---
audienceLevel: patient
cancerTypes:
- esophageal
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- cancer-type
title: Esophageal Cancer Research - NCI
url: https://www.cancer.gov/types/esophageal/research
version: v1
---

# Esophageal Cancer Research - NCI

# Esophageal Cancer Research

- [Trial Establishes Preferred Treatment for Some People with Esophageal Cancer](/news-events/cancer-currents-blog/2024/esophageal-cancer-flot-perioperative-chemotherapy)

Posted: July 9, 2024

For people with locally advanced esophageal cancer, a chemotherapy regimen called FLOT is the preferred treatment, according to results from a large clinical trial. People treated with FLOT lived much longer than those treated with the CROSS regimen.
- [Nivolumab-Based Combinations Improve Survival in Advanced Esophageal Cancer](/news-events/cancer-currents-blog/2021/esophageal-cancer-nivolumab-combinations)

Posted: June 17, 2021

A treatment regimen that combines the immunotherapy drug nivolumab (Opdivo) with either another immunotherapy drug or chemotherapy may be a new initial treatment option for people with advanced esophageal cancer, a large clinical trial finds.
- [For Esophageal Cancer, Immunotherapy Likely to Play Larger Role](/news-events/cancer-currents-blog/2020/esophageal-cancer-immunotherapy-pembrolizumab-nivolumab)

Posted: October 19, 2020

For some people with advanced esophageal cancer, the immunotherapy drugs pembrolizumab (Keytruda) and nivolumab (Opdivo) may become part of early treatment for the disease, according to results from two large clinical trials.
- [Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer](/news-events/cancer-currents-blog/2019/pembrolizumab-esophageal-fda-approval)

Posted: August 28, 2019

FDA has approved the immunotherapy drug pembrolizumab (Keytruda) to treat some patients with advanced esophageal cancer. Patients must have certain levels of the protein PD-L1 on their tumors, as determined by an FDA-approved test.
- [Genome Study Points to New Subtypes of Esophageal Cancer](/news-events/cancer-currents-blog/2017/esophageal-genomic-subtypes)

Posted: January 25, 2017

A new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.
- [Preoperative Chemotherapy, Radiation Improve Survival in Esophageal Cancer (Updated)](/types/esophageal/research/preop-treatment-improves-survival)

Updated: August 31, 2015

Patients with esophageal cancer who received chemotherapy and radiation before surgery survived, on average, nearly twice as long as patients treated with surgery alone, according to results of a randomized clinical trial published May 31, 2012, in the New England Journal of Medicine.
